Andere Sprachen Agilent Technologies, Inc.

Aktien

929138

US00846U1016

A

Medizinische Ausrüstung

Markt geschlossen - Nyse Andere Börsenplätze 22:00:03 13.02.2026			% 5 Tage	Veränd. 1. Jan.
125,81 ^USD	+0,74 %		-2,91 %	-7,54 %

11.02.	Agilent Technologies Inc. kündigt Bardividende an, zahlbar am 22. April 2026	CI
11.02.	Agilent verleiht Boehringer Ingelheim den ersten Trade-in Impact Award 2025 für Instrumente	RE

Andere Sprachen

12.02.	Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
11.02.	Agilent Announces Cash Dividend of 25.5 Cents per Share
11.02.	Agilent Technologies Inc. Announces Cash Dividend, Payable on April 22, 2026
11.02.	Agilent presents Boehringer Ingelheim with inaugural 2025 instrument Trade-in Impact Award
11.02.	Agilent Technologies, Inc. Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
11.02.	Agilent's Ovarian Cancer Diagnostic Test Receives FDA Clearance
11.02.	Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC)
11.02.	Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
11.02.	Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
10.02.	Agilent Technologies : Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
10.02.	FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma
04.02.	Agilent Technologies Inc. Showcases Next-Generation Automated Solutions at SLAS2026
04.02.	Agilent Showcases Next‑Generation Automated Solutions at SLAS2026
03.02.	Agilent Technologies : and Virscidian Announce Collaboration to Streamline Access to OpenLab CDS Data in Analytical Studio
02.02.	Agilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25
23.01.	Agilent Technologies Launches Slide Scanner System in Europe
23.01.	Agilent Technologies, Inc. Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System
23.01.	Agilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System
12.01.	Macom Technology Solutions Holdings, Inc. Appoints Bryan Ingram as Independent Director, Effective January 12, 2026
12.01.	NeoGenomics, Inc. Announces Chief Financial Officer Changes
12.01.	NeoGenomics, Inc. Announces Executive Changes
22.12.	Agilent Technologies : Annual Report for Fiscal Year Ending October 31, 2025 (Form 10-K)
22.12.	Tranche Update on Agilent Technologies, Inc. (NYSE:A)'s Equity Buyback Plan announced on January 9, 2023.
22.12.	Tranche Update on Agilent Technologies, Inc. (NYSE:A)'s Equity Buyback Plan announced on May 29, 2024.
19.12.	Wasatch BioLabs Announces Co-Marketing Agreement with Agilent Technologies to Advance Native-Read Targeted Sequencing

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen MarketScreener Artikel MarketScreener Analysen Trading-Ideen

Andere Sprachen Agilent Technologies, Inc.

Aktien

929138

US00846U1016

A

Medizinische Ausrüstung

Andere Sprachen

Filter